Nu Med Financials
| NUMD Stock | USD 0.01 0 10.00% |
With this module, you can analyze NUMD financials for your investing period. You should be able to track the changes in Nu Med individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
NUMD |
The data published in Nu Med's official financial statements typically reflect Nu Med's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Nu Med's quantitative information. For example, before you start analyzing numbers published by NUMD accountants, it's essential to understand Nu Med's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Please note, the presentation of Nu Med's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nu Med's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Nu Med's management manipulating its earnings.
Nu Med Stock Summary
Nu Med competes with InspireMD, Beyond Air, Vivos Therapeutics, MaxCyte, and DexCom. Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah. Nu Med operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 2 people.| Instrument | USA OTC Stock View All |
| Exchange | OTCQB Exchange |
| ISIN | US67021R1041 |
| Business Address | 455 East 500 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Benchmark | Dow Jones Industrial |
| Website | www.nu-medplus.com |
| Phone | 801 746 3570 |
| Currency | USD - US Dollar |
Nu Med Key Financial Ratios
There are many critical financial ratios that Nu Med's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Nu Med Plus reports annually and quarterly.| Return On Equity | -545.23 | |||
| Return On Asset | -6.62 | |||
| Beta | 0.52 | |||
| Z Score | 38.4 |
NUMD Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nu Med's current stock value. Our valuation model uses many indicators to compare Nu Med value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nu Med competition to find correlations between indicators driving Nu Med's intrinsic value. More Info.Nu Med Plus is considered to be number one stock in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nu Med's earnings, one of the primary drivers of an investment's value.Nu Med Plus Systematic Risk
Nu Med's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Nu Med volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Nu Med Plus correlated with the market. If Beta is less than 0 Nu Med generally moves in the opposite direction as compared to the market. If Nu Med Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Nu Med Plus is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Nu Med is generally in the same direction as the market. If Beta > 1 Nu Med moves generally in the same direction as, but more than the movement of the benchmark.
Nu Med December 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Nu Med help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Nu Med Plus. We use our internally-developed statistical techniques to arrive at the intrinsic value of Nu Med Plus based on widely used predictive technical indicators. In general, we focus on analyzing NUMD OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Nu Med's daily price indicators and compare them against related drivers.
| Information Ratio | (0.10) | |||
| Maximum Drawdown | 69.08 | |||
| Value At Risk | (20.34) | |||
| Potential Upside | 18.56 |
Complementary Tools for NUMD OTC Stock analysis
When running Nu Med's price analysis, check to measure Nu Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nu Med is operating at the current time. Most of Nu Med's value examination focuses on studying past and present price action to predict the probability of Nu Med's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nu Med's price. Additionally, you may evaluate how the addition of Nu Med to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |